198 related articles for article (PubMed ID: 17179199)
21. Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy.
Gleeson HK; Gattamaneni HR; Smethurst L; Brennan BM; Shalet SM
J Clin Endocrinol Metab; 2004 Feb; 89(2):662-6. PubMed ID: 14764778
[TBL] [Abstract][Full Text] [Related]
22. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
Colmenares A; González L; Gunczler P; Lanes R
J Pediatr Endocrinol Metab; 2012; 25(7-8):651-7. PubMed ID: 23155689
[TBL] [Abstract][Full Text] [Related]
23. Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group.
de Muinck Keizer-Schrama SM; Rikken B; Wynne HJ; Hokken-Koelega AC; Wit JM; Bot A; Drop SL
J Clin Endocrinol Metab; 1992 Apr; 74(4):898-905. PubMed ID: 1548357
[TBL] [Abstract][Full Text] [Related]
24. Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study.
Brownstein CM; Mertens AC; Mitby PA; Stovall M; Qin J; Heller G; Robison LL; Sklar CA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4422-7. PubMed ID: 15356041
[TBL] [Abstract][Full Text] [Related]
25. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency.
Kawai N; Kanzaki S; Takano-Watou S; Tada C; Yamanaka Y; Miyata T; Oka M; Seino Y
J Clin Endocrinol Metab; 1999 Jan; 84(1):82-9. PubMed ID: 9920066
[TBL] [Abstract][Full Text] [Related]
26. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
27. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database).
Geffner M; Lundberg M; Koltowska-Häggström M; Abs R; Verhelst J; Erfurth EM; Kendall-Taylor P; Price DA; Jonsson P; Bakker B
J Clin Endocrinol Metab; 2004 Nov; 89(11):5435-40. PubMed ID: 15531494
[TBL] [Abstract][Full Text] [Related]
28. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables.
Ranke MB; Lindberg A;
J Clin Endocrinol Metab; 2010 Mar; 95(3):1229-37. PubMed ID: 20097713
[TBL] [Abstract][Full Text] [Related]
29. Adult height in patients with permanent growth hormone deficiency with and without multiple pituitary hormone deficiencies.
Maghnie M; Ambrosini L; Cappa M; Pozzobon G; Ghizzoni L; Ubertini MG; di Iorgi N; Tinelli C; Pilia S; Chiumello G; Lorini R; Loche S
J Clin Endocrinol Metab; 2006 Aug; 91(8):2900-5. PubMed ID: 16684828
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the growth response of children with growth hormone deficiency according to the peak growth hormone levels in provocation tests.
Donbaloğlu Z; Singin B; Acar S; Bedel A; Barsal Çetiner E; Aydın Behram B; Parlak M; Tuhan H
Arch Pediatr; 2023 Nov; 30(8):573-579. PubMed ID: 37802668
[TBL] [Abstract][Full Text] [Related]
31. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children.
Bakker B; Frane J; Anhalt H; Lippe B; Rosenfeld RG
J Clin Endocrinol Metab; 2008 Feb; 93(2):352-7. PubMed ID: 18000092
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of hypophyseal dwarfism with biosynthetic growth hormone].
Blümel P; Stögmann W
Wien Klin Wochenschr; 1989 Dec; 101(24):861-3. PubMed ID: 2623878
[TBL] [Abstract][Full Text] [Related]
33. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
Ranke MB; Lindberg A; Price DA; Darendeliler F; Albertsson-Wikland K; Wilton P; Reiter EO;
Horm Res; 2007; 68(2):53-62. PubMed ID: 17228181
[TBL] [Abstract][Full Text] [Related]
34. Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency.
Lagrou K; Xhrouet-Heinrichs D; Massa G; Vandeweghe M; Bourguignon JP; De Schepper J; de Zegher F; Ernould C; Heinrichs C; Malvaux P; Craen M
J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1249-60; discussion 1261-2. PubMed ID: 11964020
[TBL] [Abstract][Full Text] [Related]
35. Free/dissociable insulin-like growth factor (IGF)-I, not total IGF-I, correlates with growth response during growth hormone treatment in children born small for gestational age.
Bannink EM; van Doorn J; Mulder PG; Hokken-Koelega AC
J Clin Endocrinol Metab; 2007 Aug; 92(8):2992-3000. PubMed ID: 17504895
[TBL] [Abstract][Full Text] [Related]
36. Response to growth hormone with respect to pubertal status on increased dose in idiopathic growth hormone deficiency: an analysis of Turkish children in the KIGS database (Pfizer International Growth Study).
Darendeliler F; Berberoğlu M; Ocal G; Adiyaman P; Bundak R; Günöz H; Baş F; Darcan S; Gökşen D; Arslanoğlu I; Yildiz M; Ercan O; Ercan G; Ozerkan E; Can S; Böber E; Adal E; Sarikaya S; Dallar Y; Siklar Z; Bircan I; Bideci A; Yüksel B; Büyükgebiz A
J Pediatr Endocrinol Metab; 2005 Oct; 18(10):949-54. PubMed ID: 16355808
[TBL] [Abstract][Full Text] [Related]
37. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database).
Ranke MB; Lindberg A; Cowell CT; Wikland KA; Reiter EO; Wilton P; Price DA;
J Clin Endocrinol Metab; 2003 Jan; 88(1):125-31. PubMed ID: 12519840
[TBL] [Abstract][Full Text] [Related]
38. Differences in serum GH cut-off values for pharmacological tests of GH secretion depend on the serum GH method. Clinical validation from the growth velocity score during the first year of treatment.
Chaler EA; Rivarola MA; Guerci B; Ciaccio M; Costanzo M; Travaglino P; Maceiras M; Pagani S; Meazza C; Bozzola E; Barberi S; Bozzola M; Belgorosky A
Horm Res; 2006; 66(5):231-5. PubMed ID: 16912509
[TBL] [Abstract][Full Text] [Related]
39. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement.
Gleeson HK; Stoeter R; Ogilvy-Stuart AL; Gattamaneni HR; Brennan BM; Shalet SM
J Clin Endocrinol Metab; 2003 Aug; 88(8):3682-9. PubMed ID: 12915655
[TBL] [Abstract][Full Text] [Related]
40. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
